JP2003517434A5 - - Google Patents

Download PDF

Info

Publication number
JP2003517434A5
JP2003517434A5 JP2000546772A JP2000546772A JP2003517434A5 JP 2003517434 A5 JP2003517434 A5 JP 2003517434A5 JP 2000546772 A JP2000546772 A JP 2000546772A JP 2000546772 A JP2000546772 A JP 2000546772A JP 2003517434 A5 JP2003517434 A5 JP 2003517434A5
Authority
JP
Japan
Prior art keywords
hydroxyomeprazole
pharmaceutically acceptable
acceptable salt
effective amount
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000546772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003517434A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/009814 external-priority patent/WO1999056746A1/en
Publication of JP2003517434A publication Critical patent/JP2003517434A/ja
Publication of JP2003517434A5 publication Critical patent/JP2003517434A5/ja
Pending legal-status Critical Current

Links

JP2000546772A 1998-05-05 1999-05-05 ヒドロキシオメプラゾール組成物及びその使用 Pending JP2003517434A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8425898P 1998-05-05 1998-05-05
US60/084,258 1998-05-05
PCT/US1999/009814 WO1999056746A1 (en) 1998-05-05 1999-05-05 Hydroxyomeprazole compositions and uses

Publications (2)

Publication Number Publication Date
JP2003517434A JP2003517434A (ja) 2003-05-27
JP2003517434A5 true JP2003517434A5 (enExample) 2006-06-15

Family

ID=22183810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000546772A Pending JP2003517434A (ja) 1998-05-05 1999-05-05 ヒドロキシオメプラゾール組成物及びその使用

Country Status (9)

Country Link
US (2) US6294586B1 (enExample)
EP (1) EP1082114B1 (enExample)
JP (1) JP2003517434A (enExample)
AT (1) ATE222764T1 (enExample)
AU (1) AU748872B2 (enExample)
CA (1) CA2330049A1 (enExample)
DE (1) DE69902657T2 (enExample)
ES (1) ES2182524T3 (enExample)
WO (1) WO1999056746A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420435B1 (en) * 1999-11-01 2002-07-16 Joe S. Wilkins, Jr. Method for treating gastrointestinal disorders
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7041706B2 (en) * 2002-04-19 2006-05-09 Wilkins Jr Joe S Method for treating crohn's disease
US9060959B2 (en) * 2003-01-24 2015-06-23 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Synergistic compositions and method for potentiating anti-oxidative activity
EP1667681A4 (en) * 2003-10-03 2009-09-30 Astron Res Pvt Ltd NEW TRANSMUCOSAL ADMINISTRATION SYSTEM
ES2281292B1 (es) * 2006-03-08 2008-06-16 Quimica Sintetica S.A. Nuevas sales de esomeprazol. procedimiento de preparacion y composiciones farmaceuticas que las comprenden.

Similar Documents

Publication Publication Date Title
JP4818516B2 (ja) 化合物の抗菌剤としての新規な使用
US20100048518A1 (en) Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent
RU2227033C2 (ru) Тауролидин и/или таурултам при лечении инфекционной язвенной болезни или инфекционного гастрита
ATE124626T1 (de) Verwendung von triclosan zur behandlung von krankheiten des gastrointestinaltraktes.
JP2005508338A5 (enExample)
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
RU2001119054A (ru) Калиевая соль (S)-омепразола
RU99118887A (ru) Применение ингибиторов желудочно-кишечной липазы
JP2002527474A5 (ja) 躁病および双極性障害の治療のための医薬
JP2002535401A5 (enExample)
RU2001107149A (ru) Тауролидин и/или таурултам против инфекционной язвенной болезни или инфекционного гастрита
RU93055870A (ru) Производные бифенила, способ их получения и фармацевтическая композиция для лечения гипертонии и сердечных заболеваний
JP2002542248A5 (enExample)
JPH04230330A (ja) 非ステロイド系抗炎症薬によつて起こる胃腸症候の緩和のための薬剤配合物と緩和法
JP2005526053A5 (enExample)
RU2006115784A (ru) Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта
JP2009517411A5 (enExample)
JP2003517434A5 (enExample)
RU2008102911A (ru) Фармацевтические составы на основе гуанфацина, подходящие для ежедневного введения в виде единичной дозированной формы
US20120122919A1 (en) Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist
JPH06503806A (ja) 胃腸疾病を処置するための5―ジフルオロメトキシ―2―[(3,4―ジメトキシ―2―ピリジル)メチルスルフィニル]ベンズイミダゾール及び抗ヘリコバクター剤含有医薬組成物
RU2005122465A (ru) (-)-энантиомер тенатопразола и его применение в терапии
RU2002121267A (ru) Способ профилактики и лечения язв желудка у животных
KR101186034B1 (ko) 위식도 역류 치료에서의 테나토프라졸의 용도
RU2009149637A (ru) Композиции, применимые для лечения гастроэзофагеальной рефлюксной болезни